References
- Chase T. N. Neurochemical alterations in Parkinson's disease. Neurobiology of cerbrospinal fluid, J. H. Wood. Plenum Press, New York 1980; 207–218
- Chase T. N., Ng L. K., Watanabe A. M. Parkinson's disease. Modification by 5‐hydroxytryptophan. Neurology 1972; 22(5)479–84
- Chia L. G., Cheng L. J., Chuo L. J., Cheng F. C., Cu J. S. Studies of dementia, depression, electrophysiology, and cerebrospinal fluid monoamine metabolites in patients with Parkinson's disease. Journal of the Neurological Sciences 1995; 133(1–2)73–78
- Chia L. G., Cheng F. C., Kuo J. S. Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's disease. Journal of the Neurological sciences 1993; 116(2)125–134
- Davidson D. L., Yates C. M., Mawdsley C., Pullar I. A., Wilson H. CSF studies on the relationship between dopamine and 5‐hydroxytryptamine in Parkinsonism and other movement disorders. Journal of Neurology, Neurosurgery, and Psychiatry 1977; 40(12)1136–41
- Gaspar P., Febvret A., Colombo J. Serotonergic sprouting in primate MTP‐induced hemiparkinsonism. Experimented Brain Research 1993; 96(1)100–6
- Gatto E. M., Fernandez Pardal M., Micheli F. Exacerbation of Parkinsonism caused by fluoxetine. Medicina (Buenos Aires) 1994; 54(2): 182
- Gottfries C. G., Gottfries I., Roos B. E. Homovanillic acid and 5‐hydroxyindoleacetic acid in the cerebrospinal fluid of patients with senile dementia, presnile dementia and Parkinsonism. Journal of Neurochemistry 1969; 16: 1341–1345
- Holt A., Baker G. B. Inhibition of rat brain monoamine oxidase enzymes by fluoxetine and norfluoxetine. Naunvn Schmiedebergs Archives of Pharmacology 1996; 354(1)17–24
- Liu H., Iacono R. P., Schoonenberg T., Kumyoshi S., Buchholz J. A comparative study on neurochemistry of cerebrospinal fluid in advanced Parkinson's disease. Neuro Biology of Disease 1999; 6(1)35–42
- Iacono R. P., Kuniyoshi S. M., Ahlman J. R., Zimmerman G. J., Maeda G., Pearlstein R. D. Concentrations of indoleamine metabolic intermediates in the ventricular cerebrospinal fluid of advanced Parkinson's patients with severe postural instability and gait disorders. Journal of Neural Transmission 1997; 104(4–5)451–9
- Mayeux R., Stern Y., Cote L., Williams J. B. Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology 1984; 34(5)642–6
- Mayeux R., Stern Y., Rosen J., Leventhal J. Depression, intellectual impairment, and Parkinson disease. Neurology 1981; 31(6)645–50
- McCance‐Katz E. F., Marek K. L., Price L. H. Serotonergic dysfunction in depression associated with Parkinson's disease [see comments]. Neurology 1992; 42(9)1813–4
- Miyawaki E., Meah Y., Koller W. C. Serotonin, dopamme, and motor effects in Parkinson's disease. Clinical Neuroparmacology 1997; 20(4)300–10
- Sandyk R. Serotonergic mechanisms in levodopa‐induced “on‐off” and sleep disorders in Parkinson's disease. International Journal of Neuroscience 1988; 43(3–4)207–13
- Scatton B., Dennis T., L'Heureux R., Monfort J. C., Duyckaerts C., Javoy‐Agid F. Degeneration of noradrenergic and serotonergic but not dopaminergic neurones in the lumbar spinal cord of Parkinsonian patients. Brain Research 1986; 380(1)181–5
- Scheinin M. Monoamine metabolites in human cerebrospinal fluid: indicators of neuronal activity?. Medical Biology 1985; 63(1)1–17
- Schneider J. S. Chronic exposure to low doses of MPTP. II. Neurochemical and pathological consequences in cognitively‐impaired, motor asymptomatic monkeys. Brain Research 1990; 534(1–2)25–36
- Simons J. A. Fluoxetine in Parkinson's disease. Movement Disorders 1996; 11(5)581–2
- Sugrue M. F., Goodlet I., Mireylees S. E. On the selective inhibition of serctonin uptake in vivo by Org 6582. European Journal of Pharmacology 1976; 40(1)121–30
- Tohgi H., Abe T., Takahashi S., Takahashi J., Hamato H. Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease, and their changes after L‐dopa administration. Neuroscience Letters 1993; 159(1–2)135–8